

10/538922  
per 1.6.03 05282  
Rec'd PCT/PTO 13 JUN 2005



Europäisches  
Patentamt


European  
Patent Office

Office européen  
des brevets

Bescheinigung

Certificate

Attestation



Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02293085.3

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Best Available Copy

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

Anmeldung Nr:  
Application no.: 02293085.3  
Demande no:

Anmeldetag:  
Date of filing: 13.12.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

CENTRE NATIONAL DE  
LA RECHERCHE SCIENTIFIQUE (CNRS)  
3, rue Michel Ange  
75016 Paris  
FRANCE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Method of diagnosis of obesity

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G01N33/48

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filling/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK

## METHOD OF DIAGNOSIS OF OBESITY

The invention is in the field of human genetics and relates to new methods of diagnosis and therapy of obesity, in particular morbid obesity, based on the identification of polymorphisms in the 5' region of the *gad2* gene.

Morbid obesity is a serious disease process, in which the accumulation of fatty tissue on the body becomes excessive, interferes with, or injures the other bodily organs, and creates (or predictably will create) serious and life-threatening health problems, which are called co-morbidities.

It is said that people are morbidly obese when their Body Mass Index (BMI = height (cm) / (mass (kg))<sup>2</sup>) is equal to or over 40.

Numerous scientific studies have established that there is a genetic predisposition to morbid obesity.

15 A region of the chromosome 10 has been involved in obesity (Hager et al, Nature Genetics 1998; 20:304-38.), which has been recently confirmed in a cohort of German young obese subjects (Hinney et al. 2000, Journal of Clinical Endocrinology and Metabolism 2000 ; 85 (8): 2962-5), as well as in White Caucasians and in African Americans (Price et al. 2001, Diabetologia 1999, 42 : 20 555-9), and in the old order Amish (Hsueh et al. 2001, The Journal of Clinical Endocrinology and Metabolism 2001 ; 86(3) : 1199-1205).

Three new single nucleotide polymorphisms (SNPs) have been identified in the frame of the invention, located in this region, and more particularly in the 5' region of the *gad2* gene. These SNPs show positive association with obesity in 25 morbidly obese subjects, while other SNPs in this region do not show this association.

In the frame of the present invention, by *gad2* gene is meant to indicate a gene whose coding sequence is represented by SEQ ID N° 1.

The 5' flanking region of *gad2* gene is meant to indicate the region 30 comprising nucleotides 1-2379 of SEQ ID N° 2, and especially the region consisting in nucleotides 1-2379 of SEQ ID N° 2. Nucleotides 2380-2382 of SEQ ID N° 2 represent the start codon of the *gad2* gene (ATG).

Thus, in a first embodiment, the invention relates to a method for diagnosing a predisposition for obesity, and in particular morbid obesity, in a human subject which comprises determining whether there is a germline alteration in the sequence of the 5' flanking region of the *gad2* gene, wherein said alteration is the presence of 5 at least one of the following mutations: -243 A>G at nucleotide 2137 of SEQ ID N° 2, -1.6kb G>A at nucleotide 780 of SEQ ID N° 2, -2004 A>T at nucleotide 376 of SEQ ID N° 2, said alteration being indicative of a predisposition to obesity.

The 5' flanking region of the *gad2* gene is represented by nucleotides 1-2379 of SEQ ID N° 2, and the SNPs according to the invention are located at 10 nucleotides 376 (presence of a T in predisposed patients, and a A in non-predisposed patients), 780 (presence of a A in predisposed patients, and a G in non-predisposed patients), and 2137 (presence of a G in predisposed patients, and a A in non-predisposed patients) of SEQ ID N° 2.

The invention relates more generally to the study of the 5' promoter region 15 of the *gad2* gene. Indeed, the inventors have demonstrated that the presence of the specific SNPs indicated in the present application leads to increased binding of nuclear factors to the 5' region of the *gad2* gene, thus leading to an increase in transcription.

It is thus credible to speculate that other modifications in the promoter 20 region of the *gad2* gene, leading to a higher expression of the GAD2 protein will also lead to predisposition to obesity, due to increase in the GABA pool. Due to the orexigenic effect of GABA, this may alter feeding behavior.

Thus, in one embodiment, the invention relates to a method for diagnosing a predisposition for obesity in a human subject, wherein the level of an expression 25 product of the *gad2* gene in said sample is investigated.

The expression products according to the invention are meant to comprise RNA or protein, or what could be called "secondary" expression product, such as GABA. The latest is indeed not really an expression product of the *gad2* gene, but increase in the production of GAD2 protein leads to increase in the GABA 30 concentration.

Alteration of mRNA expression can be detected by any techniques known in the art. These include Northern blot analysis, PCR amplification and RNase protection

In one embodiment, mRNA of the sample is contacted with a *gad2* gene probe under conditions suitable for hybridization of said probe to a RNA corresponding to said *gad2* gene and hybridization of said probe is determined, and the level of signal after hybridization is compared with a standard (reference) signal

5 (which is obtained from either a non-obese patient, or an obese patient).

The hybridization complex emits a signal, which may be due to the labeling of the probe, or of the mRNA. The different labels that may be used are well known to the person skilled in the art, and one can cite  $^{32}\text{P}$ ,  $^{33}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$  or  $^{125}\text{I}$ . Non radioactive labels may be selected from ligants as biotin, avidin, streptavidin,

10 dioxygenin, haptens, dyes, luminescent agents like radioluminescent, chemoluminescent, bioluminescent, fluorescent or phosphorescent agents.

In order to identify the SNPs mentioned in the present application, it is possible to contact a *gad2* gene 5' region probe with genomic DNA isolated from said sample under conditions suitable for hybridization of said probe to said gene

15 and hybridization of said probe is determined.

Said *gad2* gene 5' region probe is either a "wild-type" DNA, (i.e. the searched SNP is not present on the probe, and hybridization occurs when no SNP according to the invention is present on the DNA in the sample) or a "mutant" one (i.e. carrying the searched SNP, and hybridization only occurs if the SNP is present

20 on the DNA in the sample).

The person skilled in the art knows the techniques to determine the allele specific probes to use in this embodiment, their lengths, or the hybridization conditions. High stringency conditions are preferable in order to prevent false positives, for example under high stringency conditions of 0.2 x SSC and 0.1 %

25 SDS at 55-65°C, or under conditions as described below.

The stringent hybridization conditions may be defined as described in Sambrook et al. ((1989) Molecular cloning : a laboratory manual. 2<sup>nd</sup> Ed. Cold Spring Harbor Lab., Cold Spring Harbor, New York.), with the following conditions: 5 x or 6 x SCC, 50-65°C. Highly stringent conditions that can also be

30 used for hybridization are defined with the following conditions: 6 X SSC, 60-65°C.

Hybridization ADN-ADN or ADN-ARN may be performed in two steps: (1) prehybridization at 42°C pendant 3 h in phosphate buffer (20 mM, pH 7.5)

containing 5 or 6 x SSC (1 x SSC corresponding to a solution 0.15 M NaCl + 0.015 M sodium citrate), 50 % formamide, 7 % sodium dodecyl sulfate (SDS), 10 x Denhardt's, 5 % dextran sulfate et 1 % salmon sperm DNA; (2) hybridization during up to 20 at a temperature of 50-65°C, more preferably 60-65°C followed by 5 different washes (about 20 minutes at in 2 x SSC + 2 % SDS, then 0.1 x SSC + 0.1 % SDS). The last wash is performed in 0.2 x SSC + 0.1 % SDS for about 30 minutes at about 50-65°C, and/or in 0.1 x SSC + 0.1 % SDS at the same temperature. These high stringency hybridization conditions may be adapted by a person skilled in the art. Indeed, the person skilled in the art is able to determine the 10 best stringency conditions by varying the concentrations in SSC and SDS and the temperature of hybridization and washings.

In another embodiment, said expression product is the polypeptide encoded by the *gad2* gene in said sample. In particular, said polypeptide may be detected by immunoblotting or immunocytochemistry.

15 Antibodies specific for GAD2 can be used to detect increased GAD2 expression. Immunological assays can be done in any convenient formats known in the art. These include Western blots, immunohistochemical assays and ELISA assays.

Thus, antibodies that react with the GAD2 polypeptide, as well as 20 reactive fragments of such antibodies, are also encompassed within the scope of the present invention. The antibodies may be polyclonal, monoclonal, recombinant, chimeric, single-chain and/or bispecific. In preferred embodiment, the antibody or fragment thereof will either be of human origin, or will be "humanized", i.e., prepared so as to prevent or minimize an immune reaction to the antibody when 25 administered to a patient.

The antibody fragment may be any fragment that is reactive with the polypeptides of the present invention. the invention also encompasses the hybridomas generated by presenting the polypeptide according to the invention or a fragment thereof as an antigen to a selected mammal, followed by fusing cells (e.g., 30 spleen cells) of the mammal with certain cancer cells to create immortalized cell lines by known techniques, such as the technique of Köhler et Milstein (1975 *Nature* 256, 495).

The antibodies according to the invention are, for example, chimeric antibodies, humanized antibodies, Fab ou F(ab')<sub>2</sub> fragments. They may be immunoconjugates or labeled antibodies, for detection purposes.

5        In another embodiment, the invention is performed by determining whether there is an alteration in the germline sequence of the *gad2* gene 5' region in said sample by observing shifts in electrophoretic mobility of single-stranded DNA from said sample on denaturing or non-denaturing polyacrylamide gels. Said single-stranded nucleic acids may be obtained after amplification of the genomic DNA,

10      using suitable primers, and denaturation (the gel and electrophoresis conditions are usually denaturing for such a purpose).

In another embodiment, the invention is performed by amplification of all or part of the *gad2* gene 5' region from said sample, and determination of the sequence 15 of said amplified DNA, for example by chain termination extenstion.

In another embodiment, allele specific oligonucleotide primers are employed to determine whether a specific *gad2* mutant allele is present in said sample, the amplification only occurring in this case. This method is well known in the art.

20      In another embodiment, all or part of the *gad2* gene 5' region from said sample is cloned to produce a cloned sequence and the sequence of said cloned sequence is determined. The cloning is performed in vectors known in the art, such as pUC or pBR vectors.

25      In general, the invention relates to a method for determining a predisposition to obesity, in particular morbid obesity, in a subject, from a sample of said subject, which comprises determining whether there is a mismatch between (1) the 5' region of the *gad2* gene genomic DNA isolated from said sample, and (2) a nucleic acid probe complementary to human wild-type 5' region of the *gad2* gene DNA, as 30 represented by SEQ ID N° 2, when molecules (1) and (2) are hybridized to each other to form a duplex, and said mismatch being due to the presence of at least one of the 3 identified SNPs, present et nucleotides 376, 780 or 2137 of SEQ ID N° 2.

In another embodiment, the invention relates to a method wherein amplification of *gad2* gene 5' flanking region sequences in said sample is carried out and hybridization of the amplified sequences to one or more nucleic acid probes issued from the wild-type *gad2* gene 5' flanking region sequence (as represented in 5 SEQ ID N° 2) or a mutant *gad2* gene 5' flanking region sequence (in which at least one of the three SNPs located at nucleotides 376, 780 or 2137 of SEQ ID N° 2 is present), is determined.

The invention also relates to a method which comprises determining *in situ* hybridization of the *gad2* gene 5' flanking region in said sample with one or more 10 nucleic acid probes issued from a wild-type or a mutant *gad2* gene 5' flanking region sequence.

The invention opens up a new area in the treatment and/or prevention of obesity, in particular morbid obesity, especially for patient in families where genetic 15 susceptibility is suspected.

Indeed, the presence of the SNPs in the 5' region of the *gad2* gene, and the data showing increased binding of nuclear factors to said region when the polymorphisms identified in the frame of the invention are present, make it likely and credible that presence of these polymorphisms increase expression of *gad2*, 20 probably through increased transcription. Furthermore, increased activity of *gad2* gene leads to increase of the GABA pool, of the orexigenic effect of GABA, which may alter feeding behavior and contribute to the development of morbid obesity for the carriers of the identified mutations.

Thus, the invention also relates to a method for screening potential obesity 25 drugs which comprises: combining (i) a compound suspected of being a obesity drug, (ii) a GAD2 polypeptide and determining the amount of binding of the GAD2 polypeptide to said compound. Indeed, inhibitors of the GAD2 enzyme will interfere with the formation of GABA and can be considered as useful drugs for treating obesity, alone or in association with other treatments.

The invention also relates to a method for screening potential obesity 30 therapeutics which comprises: combining (i) a GAD2 binding partner, (ii) a GAD2 polypeptide and (iii) a compound suspected of being a obesity therapeutic and determining the amount of binding of the GAD2 polypeptide to its binding partner.

In a particular embodiment, said binding partner is L-glutamic acid.

The invention also relates to a method for screening potential obesity therapeutics which comprises: combining (i) a *gad2* gene binding partner, (ii) a *gad2* gene and (iii) a compound suspected of being a obesity therapeutic and 5 determining the amount of binding of the *gad2* gene to its binding partner. In this embodiment, the term "*gad2* gene" must be understood as including the 5' flanking region in the *gad2* locus, which comprises the polymorphisms of the invention, especially -243 A>G.

In particular, said *gad2* gene binding partner is IK2 (Ikaros 2), the amino 10 acid sequence of which is represented by SEQ ID N° 3.

The methods for assessing the binding of a compound to a nucleic acid or a protein are well known in the art, and are preferably performed *in vitro*. A method to achieve such a goal may be to link the nucleic acid or the protein to a solid support on which the compound to test is flown, and to check the recovery of the 15 compound after passage on the support. By adjusting parameters, it is also possible to determine the binding affinity. The compounds may also be found by other methods including FRET, SPA... when the compounds and the nucleic acid or protein are labeled. The assay may also be performed on the cells containing the nucleic acid of the invention, for example on a vector according to the invention, 20 and/or expressing the protein according to the invention. This also gives the information of the capacity of the compound to go through the membrane and penetrate within cells. These cells can be bacterial cells, or mammalian cells.

The method of the invention also allows the screening, detection and/or identification of compounds able to inhibit the biological activity of the GAD2 25 protein, and in particular the increase of the amount of produced GABA.

The present invention thus allows the detection, identification and/or screening of compounds that may be useful for the treatment of diseases where V(D)J recombination and/or DNA repair is involved. Nevertheless, the compounds identified by the method according to the invention, in order to be used in a 30 therapeutic treatment, may need to be optimized, in order to have a superior activity and/or a lesser toxicity.

Indeed, the development of new drugs is often performed on the following basis:

- screening of compounds with the sought activity, on a relevant model, by an appropriate method,
- selection of the compounds that have the required properties from the first screening test (here, modulation of GAD2 or GABA production),
- determination of the structure (in particular the sequence (if possible the tertiary sequence) if they are peptides, proteins or nucleic acids, formula and backbone if they are chemical compounds) of the selected compounds,
- optimization of the selected compounds, by modification of the structure (for example, by changing the stereochemical conformation (for example passage of the amino acids in a peptide from L to D), addition of substituants on the peptidic or chemical backbones, in particular by grafting groups or radicals on the backbone, modification of the peptides (see in particular Gante "Peptidomimetics", in *Angewandte Chemie-International Edition Engl.* 1994, 33. 1699-1720),
- testing and screening of the "optimized" compounds on appropriate models that are often models nearer to the studied pathology. At this stage, one would often use animal models, in particular rodents (rats or mice) or dogs or non-human primates, that are good models of obesity, and to look for the phenotypic changes in said models after administration of the compound.

The present invention also encompasses the compounds that have been optimized after following the steps or equivalent steps as described.

The invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound identified by a method according to the invention, and to the use of a compound identified by a method according to the invention for the manufacture of a drug intended to treat and/or prevent obesity, especially morbid obesity.

The invention also relates to a method for the therapy of obesity, in particular morbid obesity, comprising administration of a compound or a pharmaceutical composition of the invention.

In order to decrease the activity of the *gad2* gene and protein, it is possible 5 to use antisense molecules, in particular complementary to the mRNA of *gad2*, in a pharmaceutical composition for treating obesity. The invention relates to a method for the therapy of obesity, comprising administration of anti-*gad2* antisense molecule or any means to decrease the amount of GAD2 protein. The person skilled in the art is aware of the means to design antisense molecules, and of the 10 modifications that can be brought to the backbones of the molecules (phosphorothioates, methylphosphonates...).

Antisense polynucleotide sequences are useful in preventing or diminishing the expression of the *gad2* gene, as will be appreciated by those skilled in the art. For example, polynucleotide vectors containing all or a portion of the *gad2* gene (or 15 other sequences from the *gad2* locus, especially the 5' flanking region) may be placed under the control of a promoter in an antisense orientation and introduced into a cell. Expression of such an antisense construct within a cell will interfere with *gad2* transcription and/or translation.

Alternatively, a "sense" strategy may be foreseen, where a nucleic acid 20 oligonucleotide or probe comprising part of the 5' region of the *gad2* gene (especially comprising the -243 A>G variant at nucleotide 2137 of SEQ ID N° 2) is introduced within the cells, in order to be competitor for binding of the nuclear factors activating transcription. The size of the fragment of the 5' flanking region of the *gad2* gene that can be used in the sense strategy is preferably about 50-150 25 bases.

The invention also relates to new animal models useful for studying obesity, where expression of the *gad2* gene is increased. In particular, expression of this gene can be increased only conditionally, using promoters that are either site- or 30 time-specific, or inducible promoters. It is thus possible to increase *gad2* expression only in the pancreas of the animals according to the invention, or in the brain. The methods to obtain animals according to the invention are known by the persons

skilled in the art, and are useful in particular for testing some drugs that can be identified according to the methods of the invention.

The insertion of a construct in the genome of an animal to obtain a transgenic animal may be performed by methods well known by the artisan in the art, and can be either random or targeted. In a few words, the person skilled in the art will construct a vector containing the sequence to insert within the genome, with an appropriate promoter, and a selection marker (for example the gene coding for the protein that gives resistance to neomycin), and may have it enter in the Embryonic Stem (ES) cells of an animal. The cells are then selected with the selection marker, and incorporated into an embryo, for example by microinjection into a blastocyst, that can be harvested by perfusing the uterus of pregnant females. Reimplantation of the embryo and selection of the transformed animals, followed by potential back-crossing makes it possible to obtain such transgenic animal. To obtain a "cleaner" animal, the selection marker gene may be excised by use of a site-specific recombinase, if flanked by the correct sequences.

The invention thus relates to a transgenic non-human mammal having integrated into its genome the nucleic acid sequence of the *gad2* gene or the coding sequence thereof, operatively linked to regulatory elements, wherein expression of said coding sequence increases the level of the GAD2 protein and/or the GABA pool in said mammal relative to a non-transgenic mammal of the same species.

The *gad2* sequence foreseen for the preceding embodiment may be a human *gad2* gene sequence introduced within the genome of the animal of the invention, or the endogenous *gad2* gene sequence the promoter of which has been modified in order to induce overexpression. For example, the *gad2* coding sequence for mouse is known and may be found in GenBank under number NM\_008078. Other endogenous *gad2* genes in other animals may be identified using the homologies between sequences.

Furthermore, the invention also relates to a transgenic non-human mammal whose genome comprises a disruption of the endogenous *gad2* gene, as an animal model for testing links between GAD2 and obesity. In particular, said disruption comprises the insertion of a selectable marker sequence, and said disruption results

in said non-human mammal exhibiting a defect in GABA level as compared to a wild-type non-human mammal.

In particular, said disruption is a homozygous disruption, and said homozygous disruption results in a null mutation of the endogenous gene encoding 5 GAD2.

US 6,087,555 describes one way of obtaining a knock-out mouse, and the general teaching of this patent is incorporated herein by reference (column 5, line 54 to column 10 line 13). In this patent, it is described an OPG knock-out mouse, but the same method applies to a GAD2 knock-out mouse. The person skilled in the 10 art will also find information in Hogan et al. (Manipulating the Mouse Embryo: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 1986).

The mammal of the invention is preferably a rodent, especially a rat or a mouse.

15

#### DESCRIPTION OF THE FIGURES

Figure 1: schematic representation of the *gad2* gene, and of the frequency of the SNPs identified in the frame of the invention.

Figure 2: gel shift assay, testing the binding of nuclear protein in the 5' region of 20 the *gad2* gene, depending of the nature of the nucleotide at position -243. mt = mutant (G); wt = wild type (A).

Figure 3: Effect of -243A>G *gad2* variant on transcriptional activity in  $\beta$ TC3 cells. Relative Luciferase Units are expressed as means  $\pm$  S.D.

25 EXAMPLES

#### Example 1: association between obesity and SNPs

The *Gad2* gene, encodes an isoform of glutamic acid decarboxylase (GAD65), that catalyses the formation of gamma aminobutyric acid (GABA) from L glutamic acid, and is expressed in both brain and pancreatic islets cells. GABA is 30 one of the most powerful inhibitory neurotransmitters of the central nervous system (CNS). GABA modulate the gastrin's and somatostatin's secretion and may stimulate the glucose intake in several tissues (Erdo and Wolff, 1990 J Neurochem.;54(2):363-72.).

Three SNPs (-243 A>G variant (5'UTR); -1.6kb G>A (SNP 668); -2004 A>T (SNP 669)), located in the 5' flanking region of the *gad2* gene revealed positive association with obesity in morbidly obese subjects.

5 The DNA fragments bearing these polymorphisms can be amplified with the following sets of primers,

10 Polymorphisms of the *gad2* gene were genotyped by direct sequencing or by the LightCycler™ technology (Roche, Manheim, Germany). The LightCycler assay is based on hybridization probes labelled with fluorescent dyes that allow 15 fluorescence resonance energy transfer (Blomeke et al., 1999, *Anal Biochem*, 275, 93-7). SNP genotyping was carried out using melting curves analysis. PCR are performed in 9700 apparatus (Applied Biosystems, Foster city, USA) before analysis in lightCycler. Sequences of primers used for PCR and for the LightCycler assays are described in the following table.

15

SNPs	PCR primers	Primers for Light cycler assay
-243 A>G	F: 5'cctcaaatgctctggggctc3' R: 5'ggtgtcacgcaggaacagaa3'	Red640-gtctcittaaagctcccggt cgggctccgaggacccttaggttagtccc-F
-1600 G>A	F 5'ctgaggcgtattaggag R: 5'ctcctaatacgcctcag	Red640-ggaaaggcagccgcctc tggaaatgacaggcgctctggccaggcgcg-F
-2004 A>T	F: 5'tgtttcaaccactcatccat R : 5'agggacagttatgctcg	Red640-acagcctggtacagactt tgagtttcgaccacccgggctc-F

(F represents the fluorescein tag).

20 PCR amplifications were performed in a final reaction volume of 20  $\mu$ l PCR buffer, containing 50 ng human genomic DNA, 10 pmol of each primer, 2,5 mmol/l MgCl<sub>2</sub>, 2,5 mmol/l of dNTP, and 0,2 U of Taq Gold polymerase. The thermal cycling conditions for the PCR product were : 1 cycle 95°C 12 min ; 35 cycles, 95°C 15 sec, 55°C 15 sec, 72 °C 30 sec ; 1 cycle 72°C 10 min ; 1 cycle 15°C 15 min.

25 In addition, in order to study the restrained eating and "latent obesity", cognitive restraint of eating, disinhibition and hunger were analyzed according the

"Three factor eating questionnaire or TFEQ" (Stunkard AJ and Messick S, 1985 J Psychosom Res; 29(1):71-83.).

Association studies were performed in 369 morbidly unrelated obese patients (mean BMI:  $47.3 \pm 7.4 \text{ kg/m}^2$ ; mean age:  $46 \pm 12$  years; women/men, 5 294/75).

A set of 381 unrelated non obese non diabetic subjects (mean BMI:  $22.8 \pm 2.44 \text{ kg/m}^2$ ; mean age:  $58.3 \pm 14.1$  years; women/men, 228/152) was used as a control group. Table 1 shows genotype distribution and allele frequencies of the 3 SNPs (-243 A>G variant (5'UTR); -1.6kb G>A (SNP 668); -2004 A>T (SNP 10 669)).

**Table 1 .Genotype distribution and allele frequencies of 242 A>G, 1.6kb G>A and 1. 7kb A>T SNPs**

Codominant Model		Morbidly obesos BMI> 40		Controls		<i>p</i> -value
SNP	Geno-type	number of geno- types	Allele Freq.	number of geno- types	Allele Freq.	
5'UTR: -243 A>G	AA	233	A:79.9%	270	A:84.5%	<i>p</i> =0.05
	AG	117	G:20.1%	92	G:15.5%	
	GG	15		12		
SNP668: -1.6kb G>A	GG	229	G:80.2%	255	G:84.8%	<i>p</i> =0.06
	GA	13	A:19.8%	7	A:15.2%	
	AA	14		10		
SNP669: -2004 A>T	AA	221	A:80.4%	254	A:83.8%	<i>p</i> =0.19
	AT	105	T:19.6%	9	T:16.2%	
	AA	14		13		

Dominant Model		Morbidly obesos BMI> 40		Controls		<i>p</i> -value
SNP	Geno-type	number of geno- types	Allele Freq.	number of geno- types	Allele Freq.	
5'UTR: -243 A>G	AA	233	A:79.9%	270	A:84.5%	<i>p</i> =0.004
	AG/GG	132	G:20.1%	104	G:15.5%	
SNP668: -1.6kb G>A	GG	229	G:80.2%	255	G:84.8%	<i>p</i> =0.02
	GA/AA	127	A:19.8%	97	A:15.2%	
SNP669: -2004 A>T	AA	221	A:80.4%	254	A:83.8%	<i>p</i> =0.07
	AT/AA	119	T:19.6%	102	T:16.2%	

Under codominant and dominant model, the -243 A>G and the -1.6kb G>A SNP were associated with morbid obesity (respective p values of 0.004 and 0.02 under a dominant model). A trend toward association was observed for the -2004 A>T variant.

5 The relative risk of these 3 SNPs was estimated: O.R = 1.55 (95% CI [1.14 2.12]) (UTR5I; -243); O.R = 1.45 (95% CI [1.06 2]) (SNP668; -1.6kb); O.R = 1.34 (95% CI [0.97 1.84]) (SNP669; -2004).

In order to replicate these results, the 3 SNPs were genotyped in another set of 316 unrelated morbidly obese subjects. Similar result was obtained for the -243 10 A>G (under dominant model, p = 0.009) and a trend toward was obtained for the -1.6kb G>A SNP (under dominant model, p = 0.06).

Analysis of variance for obesity related phenotypes was performed (BMI, leptin, percent fat mass, insulinemia...) and significant association between the 3 SNPs and the three factors of eating behavior was found.

15 To test the human eating behavior, the subjects filled in the TFEQ (Three Factor Eating Questionnaire) questionnaire established by Stunkard et al. (*op. cit.*). The analysis of variance for three stable factors measured by TFEQ: cognitive restraint of eating (Qres), disinhibition (Qdis) and hunger (Qhun) is show in table 2. Linkage disequilibrium between the 3 SNPs was significant ( $\chi^2 = 174$ ,  $p < 10^{-10}$ ).

20 Linkage disequilibrium between each SNP was estimated by Estimation Haplotype (EH) software.  $D' = 0.84$  (SNPs -243 A>G and -1.6 kb G>T),  $D' = 0.84$  (SNPs -243 A>G and -2004 kb G>A),  $D' = 0.87$  (SNPs -1.6 kb G>T and -2004 kb G>A).

Table 2 shows the results obtained for the -243 A>G (5'UTR) variant. 25 Similar results were obtained for the -1.6kb G>A (SNP 668) and the -2004 A>T (SNP 669) variants.

**Table 2** *Analyses of variance with food intake behavior parameters.*

-243 A>G (5'UTR)				
	AA	AG	GG	P
N	233	117	15	
Age	46.02±0.78	47.82±1.1	39.9±3.1	0.04
Age-Pmax	43.5±0.79	44.3±1.1	35.76±3.1	0.03
Qres	9.53±0.31	9±0.45	6.53±1.28	0.06
Qdis	8.38±0.24	8.71±0.34	10.9±0.96	0.03
Qhun	5.29±0.24	6.49±0.35	7.95±0.95	0.001

Using a codominant model, it was found that the GG carriers presented a lower restriction score than heterozygous and wild type subjects (pvalue = 0.06). They also presented a higher disinhibition (pvalue = 0.03) and a higher hunger 5 scores (pvalue = 0.001) than heterozygous and wild type subjects. Furthermore, it was observed that GG carriers are younger (pvalue = 0.04) and seem to reach a maximal weight in early ages than AG and AA carriers (pvalue = 0.03). These data suggest that alterations of feeding behavior by *gad2* variants can contribute to the development of younger onset of morbid obesity.

10 Haplotypes studies were performed with the -243 A>G, -1.6kb G>A and the -2004 A>T variants (EHplus software). A significant haplotype frequency difference between obese and non obese subjects was observed ( $p < 10^{-10}$ ). The ATG haplotype was shown to be more frequent in obese (16.9%) compared to controls (8%) (Figure 1).

15

Example 2: Functional study of a promoter variant of *gad2* gene

To search for potential binding sites, the sequence of the 5' flanking region of the *gad2* gene was submitted to the transfac server: <http://transfac.gbf.de/cgi-bin/mat>.

20 *In silico* analyses showed that the -243 A>G (located at nucleotide 2137 of SEQ ID N° 2) and the -1.6kb G >A (located at nucleotide 780 of SEQ ID N° 2) were located near a predicted Ikaros 2 (IK2) response element site. IK2 is a transcription factor that is highly expressed in human lymphocytes, and its amino acid sequence is represented by SEQ ID N° 3.

25 In order to test if the -243 A>G variant alters nuclear protein binding to the DNA, a gel shift assay using primers with sequences of the wild type and mutated site and a nuclear extract from MIN6 cells was performed (Figure 2).

30 Results of the gel shift assay showed that there is *in vitro* binding of nuclear proteins to the IK2 responsive element site. Apparently, the nuclear proteins have a higher affinity to the response element G variant (lire 6 versus 1). Similar result were obtained with competition of the A and G allele (lire 2 vs 3; 6 vs 8; 7 vs 9).

To investigate if the allelic variant at position -243 influences GAD2 transcriptional level, transient cotransfections using firefly luciferase reporter

construct were performed to measure proximal promoter activity of wild type and variant promoters in  $\beta$ TC3 cells (murine insulinoma cell line). Renilla vector was used to normalize transfection efficiency. The transcriptional activity of -243A>G mutant construct was 8.61 times higher compared to the wild type construct (n=8, 5 p<0.0001) (Figure 3)

The observed increased transcriptional activity induced by the G allele of the -243 A>G is in concordance with the genetic results

- the association of the -243 A>G variant with obesity (p=0.004, O.R = 1.55 (95% CI [1.14-2.12]))

10 - The GG bearers have a lower food restriction score (p = 0.06), a higher disinhibition score (p = 0.03) and a higher hunger score parameter (p = 0.001).

15 These results indicate that the binding of nuclear proteins (potentially the IK2 transcription factor), in presence of variant allele, was increased and may transactivate the Gad2 gene, and thus the GABA pool. Therefore, orexigenic effect of GABA might be increased and might alter feeding behaviour and contribute to the development of morbid obesity for G carriers of the -243 A>G variant.

The result may be generalized to the other SNPs, that are also close to IK2 response element.

20

The evidence presented in this application indicates involvement of the GABA pathway in obesity in human. This is an important step towards a better understanding of the molecular mechanisms leading to common forms of obesity. It seems clear that the GABAergic neurons are involved in the integration of signals 25 modulating food intake. The identification of SNPs in the 5' region of the *gad2* gene and the demonstration that their presence modulates the expression of a key enzyme (GAD2), which in turn will modify the GABA pool opens new perspective for drugs against obesity.

## CLAIMS

1. A for diagnosing a predisposition for obesity, and in particular morbid obesity, in a human subject which comprises determining whether there is a germline alteration in the sequence of the 5' flanking region of the *gad2* gene, the coding sequence of which is represented by SEQ ID N° 1, wherein said alteration is the presence of at least one of the following mutations:  
5 -243 A>G at nucleotide 2137 of SEQ ID N° 2, -1.6kb G>A at nucleotide 780 of SEQ ID N° 2, -2004 A>T at nucleotide 376 of SEQ ID N° 2, said alteration being indicative of a predisposition to obesity.
- 10 2. The method of claim 1, wherein said obesity is morbid obesity.
- 15 3. A method for diagnosing a predisposition for obesity in a human subject, from a sample from said subject, wherein the level of an expression product of the *gad2* gene in said sample is investigated.
- 20 4. The method of claim 3, wherein said expression product is RNA or protein, or GABA.
- 25 5. A method for screening potential obesity drugs which comprises: combining (i) a compound suspected of being an obesity drug, (ii) a GAD2 polypeptide and determining the amount of binding of the GAD2 polypeptide to said compound.
- 30 6. A method for screening potential obesity therapeutics which comprises: combining (i) a GAD2 binding partner, (ii) a GAD2 polypeptide and (iii) a compound suspected of being a obesity therapeutic and determining the amount of binding of the GAD2 polypeptide to its binding partner.
7. The method of claim 6, wherein said GAD2 binding partner is L-glutamic acid.

8. A method for screening potential obesity therapeutics which comprises: combining (i) a *gad2* gene binding partner, (ii) a *gad2* gene and (iii) a compound suspected of being a obesity therapeutic and determining the amount of binding of the *gad2* gene to its binding partner.  
5
9. The method of claim 8, wherein said *gad2* gene binding partner is IK2 (Ikaros 2).
10. A pharmaceutical composition comprising a pharmaceutically acceptable excipient with a compound identified with the method according to any of claims 5 to 9.  
10
11. Use of a compound identified with the method according to any of claims 5 to 9, or of a composition according to claim 10 for the preparation of a drug intended for treatment of obesity, in particular morbid obesity.  
15
12. Use of an antisense molecule complementary to the *gad2* mRNA for the preparation of a drug intended for treatment of obesity, in particular morbid obesity.  
20
13. Use of a sense molecule comprising a fragment of the 5' flanking region of the *gad2* gene, especially comprising the -243 A>G variant (at nucleotide 2137 of SEQ ID N° 2), within said region, for the manufacture of a drug intended for the treatment of obesity.  
25
14. A transgenic non-human mammal having integrated into its genome the nucleic acid sequence of *gad2*, or coding sequence thereof, operatively linked to regulatory elements, wherein expression of said sequence increases the level of the GAD2 protein and/or the GABA pool in said mammal relative to a non-transgenic mammal of the same species.  
30

15. A transgenic non-human mammal whose genome comprises a disruption of the endogenous *gad2* gene, wherein said disruption comprises the insertion of a selectable marker sequence, and wherein said disruption results in said non-human mammal exhibiting a defect in GABA level as compared to a wild-type non-human mammal.  
5
16. The mammal of claim 14 or 15 which is a mouse.
17. Use of a mammal according to any of claims 14 to 16, as a model for studying obesity, or for testing potential anti-obesity drugs.  
10

**Abstract**

The invention relates to new methods of diagnosis and therapy of obesity, in particular morbid obesity, based on the identification of polymorphisms in the 5' region of the *gad2* gene.




Figure 1




Figure 2

3 / 3




Figure 3

## SEQUENCE LISTING

<110> CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

<120> METHOD OF DIAGNOSIS OF OBESITY

<130> 64 808 - EP

<140>

<141>

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 1758

<212> DNA

<213> Homo sapiens

<220>

<223> gad2 gene

<400> 1

atggcatctc cgggctctgg cttttggctt ttcgggtcgg aagatggctc tggggattcc 60  
gagaatcccg gcacagcgcg agctggcgc caagtggctc agaagttcac gggccggcatc 120  
ggaaacaaac tggcgccct gctctacgga gacgcccaga agccggcggg gagccggcggg 180  
agccaaacccc cgcgggcccgc cgcccgaaag gcccctgcg cctgcgacca gaagccctgc 240  
agctgctcca aagtggatgt caactacgca tttctccatg caacagacat gctccggcg 300  
tgtatggag aaaggcccac tttggcggtt ctgcaagatg ttatgaacat ttacttcag 360  
tatgttgtga aaagtttgcg tagatcaacc aaagtgattg atttccattt tcctaattgag 420  
cttctccaag aatataattt ggaattggca gaccaaccac aaaatttggg gaaaattttt 480  
atgcattgcc aacacaactct aaaatatgcg attaaaacag ggcattctag atacttcaat 540  
caacttctt cttgggttggg tatgggttggg ttagcagcag actggctgac atcaacagca 600  
aatactaaca tggcaccta tggaaatttgcg ccagtatttgc tgcttttggg atatgtcaca 660  
ctaaagaaaa tgagagaaaat cattggctgg ccaggggct ctggcgatgg gatattttct 720  
cccggtggcg ccatatctaa catgtatgcc atgatgatcg cacgctttaa gatgttccca 780  
gaagtcaagg agaaaaggaaat ggctgctt cccaggctca ttgccttcac gtctgaacat 840  
agtcattttt ctctcaagaa gggagctgca gccttagggg ttggaacaga cagcgtgatt 900  
ctgattaaat gtgatgagag agggaaaatg attccatctg atcttggaaag aaggattctt 960  
gaagccaaac agaaagggtt tggatcccttc ctcgtgatgg ccacagctgg aaccaccgtg 1020  
tacggagcat ttgacccctt cttagctgtc gctgacatgg gcaaaaagtgtaaagatctgg 1080  
atgcatgtgg atgcagctt ggggtggggg ttactgtatgt cccggaaaaca caagtggaaa 1140  
ctgagtgccg tggagagggc caactctgtg acgtggaaatc cacacaagat gatggagtc 1200  
cctttgcagt gctctgctt cttgtttaga gaagagggat tggatgcagaa ttgcaaccaa 1260  
atgcatgcct cttacctt ctagcaagat aaacattatg acctgttctt tgacactgg 1320  
gacaaggcc tacagtgcgg acgcacgtt gatgtttta aactatggct gatgtggagg 1380  
gcaaaggggg ctaccgggtt tgaagcgcattt gttgataat gtttggagtt ggcagagtt 1440  
ttataacaaca tcaaaaaaaaaa ccgagaagga tatgagatgg tggatggatgg gaagccctcag 1500  
cacacaaatg tctgcttctg gtacatttctt ccaagcttcg gtactctggaa agacaatggaa 1560  
gagagaatga gtcgccttc gaaagggtt ccagtgatta aagccagaat gatggagtt 1620  
ggaaccacaa tggtcagcta ccaacccttggagacaagg tcaatttctt ccgcattggc 1680  
atctcaaaacc cagcggcaac tccaccaagac attgacttcc tgattgaaga aatagaacgc 1740  
cttggacaag atttataaa 1758

<210> 2

<211> 2382

<212> DNA

<213> Homo sapiens

<220>  
 <223> 5' flanking region of gad2 gene nucleotides

<220>  
 <223> R = G or A

<220>  
 <223> Y = T or C

<220>  
 <223> M = A or C

<220>  
 <223> W = A or T

<220>  
 <223> S = G or C

<400> 2  
 gaaaaaaaaa tcagttaaat tcaggtgttt taatccgttt cttctttggg ggaaaaatgt 60  
 gattnaaacg cttgctttta agaaccttta tgaaaaaacaac cactcatcca tagtagaaaa 120  
 gttctgcaac cctagactgc tggcttgaag gaaaacccctt gcaggattt atatggattt 180  
 caacaaagaa ccagcctctg cgaggctgga gagagctgcg gagctgcccgcat gcctgaagt 240  
 cagatggctg aaccacaagt ctttaggttt ccggagttgt tattgtgggt acctagatg 300  
 tcagagccag gagagcaaga aagaggagcc aaactgagcc ctgagtttc gaccacccgg 360  
 gctcccacag cctggwacag acttcaccta gcacgctcag tgcacgctt cggcaggacg 420  
 ctatcaacgc cgcactggwt tcytgctc tccatctggcgc ctggggccag ttgcccatagt 480  
 gtggatccca tgactcctca gggaaacccct ggactcaggc acgcgagaag aagacagcgc 540  
 tttgtggaga gaatttgacca gggacagttt tgctcgagca cacaggactt gggcctgtat 600  
 gcgtccagca tggggcccccag gatgtccctt ctaagcgagg gtgcagggggt gtcgcggccag 660  
 acgggatccc cgggtctctg ctttggtagc agctttgggt gctggttcag gaggtcagag 720  
 aaataaaaacg acttggtaac acaatggaaa tgacaggcgc tctggccagg cgcggggaa 780  
 gcagccgcct cgggaagccg acctcagccc tttccctctc tccctccctt cctgtctcccc 840  
 cagagcccccggagactcccgag gtgcacttga agttcatc cactgcccagg agaacgcgc 900  
 gcaaactgtc aaagggtctcc caatccttag ggcgtccccc ctgtctgcaaa tagcttttg 960  
 tagaaaggaa atcatcagaa mgattctgac tttctccccc tttcttttatt agaaaaaagag 1020  
 aaaccgcctc ctaatacgc ctagagagaa ccaatctcgc gctccgggt caccgcgtac 1080  
 cgcgaagatt ctctgggggc gagggggggc attggttga agccccctaa aacgaggggcc 1140  
 ctgcaggcga tgccttctc cctactcggc tttgtaaagc cgagattgtc tagttggaaa 1200  
 ccctgttctc ccctcccccagg cgcacacaga tcccccttac acgcaaggcgc cggcgcttc 1260  
 cacgcctccg cgggccaagg tcaccaaattt ccctgatcc atccccccacc cgcctcatcaat 1320  
 cctgcgcact ctggccgcact tgcctcatc tcttccaaga agttccatt cgtttttattt 1380  
 tttttttccc agcccgagggt cctcagtaga ctccagcgtg gattttaatt gcctcaatca 1440  
 gcagtcattc tccccagccg tcactcagag cctggacgggt gggcccccgcg atctagccct 1500  
 tggctacgca ggaacgggtc gccccgggt acggggcggt tcagcaggca ggcgtcagg 1560  
 tctaccaagg cgctgaaatg agcccatcag cgggttaggag cccttcccccc gccgtccccct 1620  
 ccccaggcgc gtgaacggcg cctgatccc gccccggcg cgagctctcg aggtcgcagt 1680  
 gacctcagca cctgcttggg gaaaaacggc gccccggggcc cgcttcccttcc cctcagctg 1740  
 gagccagacc tcaaacaaaaa ccccaatcga tgcacacaga aaactctct gggccacgct 1800  
 tcccgctcg cccagggtctc cccagtcgc ccctcgtcgc cgctggcgccg cagcsgctgt 1860  
 ggcagcaccc gggacagccg ccgcggccac ttccccgcctc tggctcgccc gaggacgcgc 1920  
 tggcaacgcct cccacccctt cactctgact ccagctggcg tgcacatggctc gcctcgcatc 1980  
 ctcacgactc agctccctcc ctctctcg ttttttccct ccggccggccc ctcattcatc 2040  
 cccactggc tccctttccc tcaaatgctc tggggctctc cgccgtttcc tgagtccggg 2100  
 ctccgaggac ctttaggtag tcccggtctc ttttaargct ccccggtctt caaagggttg 2160  
 ccacgtccct aaaccctgtc tccagctcgc atacacacac gcacagacac. gcacgttttc 2220  
 tggccctgc tgacacccgc cctgcccgtt cggccccggcc ggtccccggcg cgggtccctc 2280  
 ctcccgccac acgggcacgc acgcgcgcgc agggccaagc ccgaggcagc tggccccgcag 2340

ctcgcaactcg caggcgacct gctccagtct ccaaagccga tg

2382

<210> 3  
 <211> 519  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> DNA-binding protein Ikaros (Lymphoid transcription factor LyF-1)

<400> 3  
 Met Asp Ala Asp Glu Gly Gln Asp Met Ser Gln Val Ser Gly Lys Glu  
 1 5 10 15  
 Ser Pro Pro Val Ser Asp Thr Pro Asp Glu Gly Asp Glu Pro Met Pro  
 20 25 30  
 Ile Pro Glu Asp Leu Ser Thr Thr Ser Gly Gly Gln Gln Ser Ser Lys  
 35 40 45  
 Ser Asp Arg Val Val Ala Ser Asn Val Lys Val Glu Thr Gln Ser Asp  
 50 55 60  
 Glu Glu Asn Gly Arg Ala Cys Glu Met Asn Gly Glu Glu Cys Ala Glu  
 65 70 75 80  
 Asp Leu Arg Met Leu Asp Ala Ser Gly Glu Lys Met Asn Gly Ser His  
 85 90 95  
 Arg Asp Gln Gly Ser Ser Ala Leu Ser Gly Val Gly Ile Arg Leu  
 100 105 110  
 Pro Asn Gly Lys Leu Lys Cys Asp Ile Cys Gly Ile Ile Cys Ile Gly  
 115 120 125  
 Pro Asn Val Leu Met Val His Lys Arg Ser His Thr Gly Glu Arg Pro  
 130 135 140  
 Phe Gln Cys Asn Gln Cys Gly Ala Ser Phe Thr Gln Lys Gly Asn Leu  
 145 150 155 160  
 Leu Arg His Ile Lys Leu His Ser Gly Glu Lys Pro Phe Lys Cys His  
 165 170 175  
 Leu Cys Asn Tyr Ala Cys Arg Arg Asp Ala Leu Thr Gly His Leu  
 180 185 190  
 Arg Thr His Ser Val Gly Lys Pro His Lys Cys Gly Tyr Cys Gly Arg  
 195 200 205  
 Ser Tyr Lys Gln Arg Ser Ser Leu Glu Glu His Lys Glu Arg Cys His  
 210 215 220  
 Asn Tyr Leu Glu Ser Met Gly Leu Pro Gly Thr Leu Tyr Pro Val Ile  
 225 230 235 240  
 Lys Glu Glu Thr Asn His Ser Glu Met Ala Glu Asp Leu Cys Lys Ile  
 245 250 255

Gly Ser Glu Arg Ser Leu Val Leu Asp Arg Leu Ala Ser Asn Val Ala  
 260 265 270  
 Lys Arg Lys Ser Ser Met Pro Gln Lys Phe Leu Gly Asp Lys Gly Leu  
 275 280 285  
 Ser Asp Thr Pro Tyr Asp Ser Ser Ala Ser Tyr Glu Lys Glu Asn Glu  
 290 295 300  
 Met Met Lys Ser His Val Met Asp Gln Ala Ile Asn Asn Ala Ile Asn  
 305 310 315 320  
 Tyr Leu Gly Ala Glu Ser Leu Arg Pro Leu Val Gln Thr Pro Pro Gly  
 325 330 335  
 Gly Ser Glu Val Val Pro Val Ile Ser Pro Met Tyr Gln Leu His Lys  
 340 345 350  
 Pro Leu Ala Glu Gly Thr Pro Arg Ser Asn His Ser Ala Gln Asp Ser  
 355 360 365  
 Ala Val Glu Asn Leu Leu Leu Leu Ser Lys Ala Lys Leu Val Pro Ser  
 370 375 380  
 Glu Arg Glu Ala Ser Pro Ser Asn Ser Cys Gln Asp Ser Thr Asp Thr  
 385 390 395 400  
 Glu Ser Asn Asn Glu Glu Gln Arg Ser Gly Leu Ile Tyr Leu Thr Asn  
 405 410 415  
 His Ile Ala Pro His Ala Arg Asn Gly Leu Ser Leu Lys Glu Glu His  
 420 425 430  
 Arg Ala Tyr Asp Leu Leu Arg Ala Ala Ser Glu Asn Ser Gln Asp Ala  
 435 440 445  
 Leu Arg Val Val Ser Thr Ser Gly Glu Gln Met Lys Val Tyr Lys Cys  
 450 455 460  
 Glu His Cys Arg Val Leu Phe Leu Asp His Val Met Tyr Thr Ile His  
 465 470 475 480  
 Met Gly Cys His Gly Phe Arg Asp Pro Phe Glu Cys Asn Met Cys Gly  
 485 490 495  
 Tyr His Ser Gln Asp Arg Tyr Glu Phe Ser Ser His Ile Thr Arg Gly  
 500 505 510  
 Glu His Arg Phe His Met Ser  
 515

<210> 4  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer to  
 amplify SNP - 243

<400> 4  
cctcaaatgc tctggggctc 20

<210> 5  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer to  
amplify SNP - 243

<400> 5  
ggtgtcacgc aggaacagaa 20

<210> 6  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer to  
amplify SNP - 243

<400> 6  
gtctctttta aagctcccg gct 23

<210> 7  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer to  
amplify SNP - 243

<400> 7  
cgggctccga ggacccttag gtagtccc 28

<210> 8  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer to  
amplify SNP - 1.6 kb

<400> 8  
ctgaggcgta ttaggag 17

<210> 9  
<211> 17  
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to  
amplify SNP - 1.6 kb

<400> 9

ctccttaatac gcctcag

17

<210> 10

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to  
amplify SNP - 1.6 kb

<400> 10

ggaaaggcagc cgcctc

16

<210> 11

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to  
amplify SNP - 1.6 kb

<400> 11

tggaaatgac aggcgctctg gccaggcgcg

30

<210> 12

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to  
amplify SNP - 2004

<400> 12

tgttttcaac cactcatcca t

21

<210> 13

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer to  
amplify SNP - 2004

<400> 13

aggcacagtt atgctcg

17

<210> 14  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer to  
amplify SNP - 2004

<400> 14  
acagcctggc acagactt

18

<210> 15  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer to  
amplify SNP - 2004

<400> 15  
tgagtttcg accacccggg ctc

23

PCT Application

**IB0305282**



This Page is inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLORED OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**  
**As rescanning documents *will not* correct images**  
**problems checked, please do not report the**  
**problems to the IFW Image Problem Mailbox**